How to Treat Stage 1 Hypertension

Stage 1 hypertension—defined as a sustained systolic blood pressure of 130–139 mmHg and/or diastolic blood pressure of 80–89 mmHg—is the most common form of elevated blood pressure encountered in clinical practice. While often asymptomatic, it significantly increases long-term cardiovascular risk, including for myocardial infarction, stroke, heart failure, and chronic kidney disease.

Management begins with comprehensive cardiovascular risk assessment—not just blood pressure measurement. Clinicians evaluate for comorbidities such as diabetes mellitus, dyslipidemia, chronic kidney disease, and established atherosclerotic cardiovascular disease (ASCVD), as well as lifestyle factors including diet, physical activity, tobacco use, alcohol consumption, and psychosocial stressors.

For most adults with stage 1 hypertension and low to moderate ASCVD risk, first-line therapy emphasizes nonpharmacologic interventions. These include adherence to the Dietary Approaches to Stop Hypertension (DASH) eating pattern—rich in fruits, vegetables, whole grains, and low-fat dairy while limiting sodium (<1,500 mg/day ideal; ≤2,300 mg/day recommended), added sugars, and saturated fats. Regular aerobic exercise (≥150 minutes/week of moderate-intensity activity), weight management (targeting BMI <25 kg/m²), smoking cessation, and moderation of alcohol intake (≤2 drinks/day for men, ≤1 drink/day for women) are evidence-based cornerstones.

Pharmacologic treatment is indicated for individuals with stage 1 hypertension who have established cardiovascular disease, chronic kidney disease, diabetes, or a 10-year ASCVD risk ≥10% (per ACC/AHA risk estimator). First-line antihypertensive agents include thiazide-type diuretics (e.g., chlorthalidone or indapamide), calcium channel blockers (e.g., amlodipine), angiotensin-converting enzyme inhibitors (e.g., lisinopril), or angiotensin II receptor blockers (e.g., losartan). Choice depends on patient-specific factors—including age, race, comorbidities, and tolerability—with combination therapy often required to achieve target blood pressure (<130/80 mmHg for most adults).

Successful management requires shared decision-making, regular follow-up (every 2–4 weeks initially after initiating or adjusting therapy), home blood pressure monitoring, and ongoing reinforcement of lifestyle modification. Early, consistent intervention in stage 1 hypertension not only lowers blood pressure but meaningfully reduces morbidity and mortality across the lifespan.